Ixelles Pharma SRL
2.2 FTEIxelles Pharma reported total assets of €1.03m at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Apr 2026), with 2.2 full-time equivalents.
The score of Ixelles Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +16 % Total assets -30 % Headcount (avg FTE) -31 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Ixelles Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Apr 2026
- Year ended 31 Dec 2024filed on 01 Jul 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 28 Jun 2023
- Year ended 31 Dec 2021filed on 30 May 2022
Ixelles Pharma's financial analysis
- Solvency57.7%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Ixelles Pharma
Ixelles Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0478.282.551
- VAT number
- BE0478282551
- Peppol
- Registered · 0208:0478282551 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Sep 2002
- Registered office
- 1050 Ixelles
- Size
- Micro · 2.2 FTE
- Latest accounts
- 2025 · filed on 27 Apr 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Ixelles Pharma (SRL) has been based in Ixelles since 2002, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 31,115 € and equity of 593,884 €; its revenue is not published. With 2.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 57.7%, above the median of its sector (37.8%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Ixelles Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Hittelet Retail sale of pharmaceutical products Étalle · balance sheet €1.03m
- Kruispunt Apotheek Retail sale of pharmaceutical products Antwerp · balance sheet €1.03m
- Anami Retail sale of pharmaceutical products Tielt · balance sheet €1.03m
- Apotheek de Pauw - Varsenare Retail sale of pharmaceutical products Jabbeke · balance sheet €1.03m
- Pharmatoune Retail sale of pharmaceutical products Beersel · balance sheet €1.03m
- Pharma Degee Retail sale of pharmaceutical products Andenne · balance sheet €1.03m
- Pharmapoint Retail sale of pharmaceutical products Maasmechelen · balance sheet €1.02m
- Medmex Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet €1.03m
Frequently asked questions about Ixelles Pharma
What is the revenue of Ixelles Pharma?
Ixelles Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Ixelles Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0478282551 for Ixelles Pharma, if the company is VAT-registered. Its company number (CBE) is 0478.282.551.
Where is the registered office of Ixelles Pharma?
According to the CBE register, the registered office of Ixelles Pharma is in 1050 Ixelles.
What is the equity of Ixelles Pharma?
At the close of the 2025 financial year, the equity of Ixelles Pharma amounts to 593,884 €, a solvency of 57.7% of total assets.
How many people work at Ixelles Pharma?
2.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Ixelles Pharma?
The register lists 2 active mandates at Ixelles Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Ixelles Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →